Almost all childhood HIV-1 is now acquired through vertical transmission. Identifying factors that affect the rate of transmission may lead to the initiation of specific preventive strategies. In this study, antibody levels against different neutralizing epitopes on the envelope glycoprotein of HIV-1 (gpl20) were measured in HIV-1-infected pregnant women that either transmitted HIV-1 to their infants (18 women) or did not (29 women). Differences in levels of antibodies directed against the monomeric gpl20 molecule and against the V3 loop region of gpl20 were not significantly different between the two groups studied. However, significant differences were observed in the levels of CD4 binding site antibodies, as determined by the ability of diluted maternal plasma to inhibit binding of the CD4 binding site monoclonal antibody F105 (mAb F105) to monomeric gpl20. In addition, more nontransmitting mothers had low viral load as defined by having two or more negative HIV-1 viral cultures during pregnancy compared with transmitters. This pilot study suggests that in addition to higher viral load, low levels of CD4 binding site antibodies correlate with increased risk of HIV-1 vertical transmission. Passive immunotherapy with broadly neutralizing CD4 binding site antibodies should be considered as a strategy to reduce this risk. (J. Clin. Invest. 1995. 95:732-737.)
Introduction
The vast majority of childhood HIV-1 in the United States is acquired through vertical transmission. Current estimates indicate that women now represent 12% of AIDS cases and that 75% of these women are in the child bearing age (1) . HIV-1 infection in women results in the birth of -1,800 infected infants in the United States annually (2) .
Among the most pressing questions in pediatric AIDS are why 15-25% of infants born to HIV-1 seropositive mothers acquire HIV-1 while the majority of infants do not become infected, and why rates of transmission apparently vary widely among populations on a global basis. Only limited data are currently available on factors affecting HIV-1 vertical transmission. Two recent studies showed that maternal viral load and degree of immune deficiency are associated with greater risk of transmission (3, 4) . In another study, the level of p24 antigenemia, high CD8 lymphocyte counts, and the presence of placental inflammation correlated with the highest transmission rate (5) . Other studies reported a positive correlation between the presence of other sexually transmitted diseases (6) or high maternal IgA levels and vertical transmission (7) .
The role that maternal neutralizing antibodies play in vertical transmission continues to be an area of great interest since the protective role of maternal immunity is well established in a number of other congenitally transmitted infections. Most of the neutralizing antibodies generated against HIV-1 are directed against epitopes on the envelope glycoproteins, gpl20 and gp41. The humoral immune response to gpl20 involves the production of at least two classes of neutralizing antibodies (8) . One class is directed against epitopes on the third hypervariable loop of gpl20 (8, 9) . These antibodies appear early after infection, are usually (but not always) strain specific, and may become less imnportant later in infection because of the emergence of escape mutants (10) . The presence of these antibodies does not correlate with reduced vertical transmission rate (11, 12) . Another class of neutralizing antibodies appears later in the course of HIV-1 infection and is more broadly neutralizing. A subset of these antibodies interferes with the binding of gpl20 to the CD4 receptor (CD4 binding site antibodies) (13) (14) (15) (16) (17) (18) . These antibodies neutralize a large array of primary and laboratory strains of HIV-1. Lack of these antibodies is associated with disease progression in adults ( 19) . Their role in HIV-1 vertical transmission, however, has not been explored.
This study was undertaken to identify factors that may affect HIV-1 vertical transmission. Plasma samples from HIV-1-infected women were tested for the levels of total anti-gpl20 antibodies and subsets of these antibodies that are directed against the V3 loop and CD4 binding sites. The results of these tests, along with measures of viral load and immune competence, were then correlated with vertical transmission.
Methods
Maternal plasma samples were obtained through a collaborative investigation with the Women Infants Transmission Study, a multicenter study on HIV-1 vertical transmission. The HIV-1 status of women enrolled was established by the standard serologic assays. Seropositive mothers were classified as transmitters when their infants had two or more posi- (19) . Specificity of B-F105 binding to the CD4 binding site of gpl20 was confirmed by demonstrating that both soluble CD4 and unlabeled F105 inhibit the binding of B-F105 to gpl20 (data not shown). Immulon 1 "U" ELISA plates (Dynatech Laboratories Inc., Chantilly, VA) were coated with recombinant monomeric gpl20 of the IIIB strain (American Biotechnology, Cambridge, MA) in 100 mM NaHCO3, pH 9.0, at 100 pl/well (100 ng/well). Plates were incubated overnight at 4°C and washed with TBS (144 mM NaCl, 25 mM Tris, pH 7.5) containing 0.1% Tween 20 (TBS-T) (Sigma Immunochemicals, St. Louis, MO). Plates were then blocked with 1% bovine serum albumin (BSA) (Sigma Immunochemicals) in TBS-T. Plasma samples were diluted at 1:300 in 0.005% BSA in PBS containing 100 ng/ml of B-F105 (the amount required for half-maximum binding [17] ) and allowed to incubate overnight at 40C. For (24) . Viral culture. Viral cultures were performed by cocultivating patients PBMCs with PHA-stimulated PBMCs from HIV-l -negative donors as described (25) .
Statistical analysis. X square, Fisher exact, and t tests assuming unequal variances were used for analysis (26) .
Results
In this retrospective review, antibody levels and other clinical and laboratory data of 18 transmitters and 29 of 61 nontransmitters were analyzed. Samples collected from nine HIV-1 -negative pregnant women were used as a negative control. A total of 104 plasma specimens was tested from seropositive mothers A, F105 competitive inhibition assay revealed significant differences between the two groups (P = 0.024). B, sCD4 blocking assay, no significant difference was noted (0.063) although a trend toward higher levels in nontransmitters was seen. C and D, Antigpl20 and anti-V3 loop assays, respectively, showed no significant differences although a trend toward lower levels was noted in nontransmitters. Higher mean and median B-F105 inhibition levels were observed in the nontransmitting group (mean 59+22% SD, median 69%) compared with the transmitting group (mean 40±29%, median 40%). The differences were significant (P = 0.024) (Fig. 1 A) . Furthermore, a greater percentage of transmitting mothers had significantly lower inhibition levels at each cumulative percent B-F105 inhibition level that was examined (Table LI) . Soluble CD4 (sCD4) blocking assay. The sCD4 blocking levels for the 47 patients varied between 0 and 85% (Fig. 1  B) . In 28/31 (90%) of women who provided multiple samples during pregnancy, the subsequent blocking levels did not vary by > 10% compared with the initial sample tested, indicating that there was little change in the blocking levels during pregnancy. Nontransmitters as a group had higher blocking levels (mean 63+14%, median 66%) compared with transmitters (mean 52+21%, median 60%) although the differences were not significant (P = 0.063). Analysis of data at different cumulative percent sCD4 blocking cutoffs did not reveal a statistically significant difference between the sCD4 blocking levels of transmitters versus nontransmitters, although a trend toward lower levels in the transmitter group was seen (Table III) . There were four women with both F105 inhibition and sCD4 blocking levels below 30% and all four were transmitters.
Anti-gp120 assay. Absorbance of all samples ranged from 0.1 to 1.3 ( Fig. 1 C) . Transmitters had higher anti-gpl20 mean but lower median levels compared with nontransmitters (0.55±0.47 and 0.36 versus 0.47+0.36 and 0.41, respectively). In women who provided multiple samples, there was no change in the anti-gpl20 level throughout pregnancy. No significant difference was observed in the levels of transmitting versus nontransmitting mothers when analyzed at three different cumulative absorbance cutoffs (Table IV) .
Anti-V3 loop assay. Absorbance of samples tested ranged from 0.1 to 1.1 (Fig. 1 D) . Transmitters had higher anti-V3 loop mean and median levels compared with nontransmitters transmitters had absolute CD4 counts of < 200 cell/mm3 compared with 3 of 29 (14%) nontransmitters (P = 0.67). 7 (58%) of transmitters and 14 (64%) of nontransmitters had CD4+ lymphocyte counts of < 500 cells/mm3 (P = 0.57).
Immunoglobulin level. The mean and median total IgG levels for the whole cohort were 1,673 and 1,775 g/dl, respectively. The transmitter group mean and median IgG levels were 1,860 and 1,820 g/dl, respectively, compared with 1,578 and 1,490 g/dl of nontransmitters. The IgG levels of women who had low F105 inhibition and low CD4 blocking levels (< 50%) ranged 
Discussion
It is known that 15-25% of infants bom to HIV-1-positive mothers become infected (27) (28) (29) (30) , but only limited data are available on what factors either allow or prevent vertical transmission to occur. One of the possible protective factors is the presence of maternal neutralizing antibodies that may reduce viral load and block cell-free transmission. Establishing a correlation between neutralizing antibody levels and transmission rate will be critically important to support the rationale for clinical trials of pregnant HIV-l-infected women with passive immunotherapy.
In this study we examined the presence of CD4 binding site antibodies in maternal plasma samples of women who did or did not transmit HIV-1 to their infants. A correlation was found between low inhibition levels of antibodies that overlap the F105 binding site and vertical transmission. In addition, there was a trend toward lower levels of antibodies that block CD4 binding to gp 120 in transmitters compared with nontransmitters. F105 is a representative of a subset of these antibodies and binds to a discontinuous epitope that overlaps with, yet has distinct binding characteristics from, the CD4 binding site (31-33) (see below). Furthermore, the four patients who had low levels of both F105 inhibition and sCD4 blocking were all transmitters. These findings are in agreement with recently published data that demonstrated lower rates of transmission in women whose plasma was able to neutralize autologous and heterologous HIV-1 isolates (34) . All of the eight women who had two or more negative HIV-1 viral cultures during pregnancy had a F105 inhibition or CD4 blocking levels that exceeded 30%, suggesting a correlation between low viral load and the presence of CD4 binding site antibodies.
One major obstacle in the development of effective passive therapy is the high rate of mutation and the antigenic variability of HIV-1 particularly for passive therapy directed against the hypervariable V3 loop. It has been shown that although neutralizing antibodies to the primary virus isolates are detectable 13-45 wk after seroconversion, escape viruses with reduced sensitivity to neutralization by autologous sera emerge rapidly (35) . Patients subsequently develop neutralizing antibodies to the escape virus after a delay. Because of the rapid emergence of escape mutants, an ideal choice for passive immunotherapy would be antibodies that neutralize through binding to conserved epitopes on HIV-1. Antibodies directed against the CD4 binding site have the ability to react with and neutralize a wide range of HIV-1 isolates. Antibodies of this class are potentially able to react with and neutralize the V3 loop escape mutants since the CD4 attachment site on gpl2O is thought to be highly conserved (31) (32) (33) . The CD4 binding site on gpl20 does not represent a single epitope but instead appears to represent an "'epitope cluster" (8, (31) (32) (33) . Both polyclonal antibodies purified from HIV-1-infected patient sera and human monoclonal antibodies derived from HIV-1-infected patient directed against this region neutralize many (but not all) laboratory and primary strains of HIV-1 (16) (17) (18) (36) (37) (38) (39) .
Recent data suggest that HIV-1 can be transmitted from mother to infant through either cell-free or cell-associated virus (40) . In the work reported here, the latter pattern may explain HIV-1 vertical transmission in mothers with high levels of CD4 binding site antibodies since the presence of high titer of neutralizing antibodies may not be sufficient to prevent cell-associated transmission. On the other hand, low levels of neutralizing antibodies will likely increase the risk of cell-free transmission, a process that can potentially be reversed by passive immunotherapy. Such protection has been reported in chimpanzees that were infused with neutralizing antibodies (41, 42). In addition, it is possible that the higher levels of neutralizing antibodies that can be achieved through passive immunotherapy may be effective in protection. This strategy has been effective in reducing the risk of hepatitis B virus transmission from mother to newborn (43) .
In summary, this study demonstrates that low levels of a subset of anti-gpl20 antibodies that overlap with the F105 epitope are correlated with HIV-1 vertical transmission. The variability of CD4 binding site antibody levels in this patient population may reflect different stages of HIV-1 disease: this class of antibodies is prevalent during the asymptomatic stage, but absent both early after infection and in the later stages of disease (11, 17, 19) . Because of the complexity of factors that may affect the rate of vertical transmission, it is unlikely that passive immunotherapy alone will eliminate the risk of transmission. It may, however, reduce the probability of transmission, especially if transmission is due to cell-free virus. As the success of passive immunotherapy depends on the choice of antigenic determinants, it is essential to investigate further the role of CD4 binding site and other classes of neutralizing antibodies in this patient population.
